University of Kentucky

UKnowledge
Markey Cancer Center Faculty Publications

Markey Cancer Center

1-2019

P4HA1 is a New Regulator of the HIF-1 Pathway in Breast Cancer
Ren Xu
University of Kentucky, ren.xu2010@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub
Part of the Cell and Developmental Biology Commons, and the Oncology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Xu, Ren, "P4HA1 is a New Regulator of the HIF-1 Pathway in Breast Cancer" (2019). Markey Cancer Center
Faculty Publications. 146.
https://uknowledge.uky.edu/markey_facpub/146

This Review is brought to you for free and open access by the Markey Cancer Center at UKnowledge. It has been
accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

P4HA1 is a New Regulator of the HIF-1 Pathway in Breast Cancer
Digital Object Identifier (DOI)
https://doi.org/10.15698/cst2019.01.173

Notes/Citation Information
Published in Cell Stress, v. 3, no. 1, p. 27-28.
© 2019 Xu.
This is an open-access article released under the terms of the Creative Commons Attribution (CC BY)
license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are acknowledged.

This review is available at UKnowledge: https://uknowledge.uky.edu/markey_facpub/146

Microreview
www.cell-stress.com

P4HA1 is a new regulator of the HIF-1 pathway in
breast cancer
Ren Xu1,2,*
1

Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA.
* Corresponding Author:
Ren Xu, Markey Cancer Center, University of Kentucky, Lexington, KY 40536; E-mail: ren.xu2010@uky.edu
2

Hypoxia-Inducible Factor (HIF)-1 is a transcription factor that plays the key role in response to low oxygen
concentrations, or hypoxia. Activation of the HIF-1
pathway is not only crucial for normal tissue development and function, but also involved in disease progression, such as cancer. Cancer cells proliferate rapidly in solid tumors, and thus, solid tumors consume
much more oxygen and nutrients than normal tissue
and generate oxygen tension. It is well established that
oxygen tension in solid tumor tissue induces the aberrant activation of the HIF-1 pathway, and subsequently
promotes angiogenesis and tumor progression. Breast
cancer is a heterogeneous disease and can be classified
into luminal, Her2 positive, and triple negative (TNBC)
subtypes base on ER/PR and Her2 expression in the
breast cancer tissue. HIF-1 activation is observed in all
breast cancer subtypes; interestingly, the HIF-1 pathway is hyperactivated in TNBCs compared to other
subtypes. The differential activation of the HIF-1
pathway in breast cancer subtypes suggests that oxygen-independent pathways may be involved in HIF-1
regulation during TNBC progression. However, these
pathways have not been well-characterized. We
demonstrate that collagen proly 4 hydroxylase 1
(P4H1) induces HIF-1α expression at the protein level
by modulating α-ketoglutarate (α-KG) and succinate
levels. These results reveal a novel link between collagen hydroxylation and activation of the HIF-1 pathway
and unveil a new HIF-1 regulation mechanism in TNBC.
Prolyl hydroxylation is a very common posttranslational
protein modification. About 4% amino acid residues in animal proteins are hydroxyproline, and most of hydroxyproline is within collagen. Regulation of protein stability and

folding is the two major functions for prolyl hydroxylation.
For instance, the hydroxylation on proline 402 (Pro402)
and 564 (Pro564) induces ubiquitination and degradation
of HIF-1α, and the hydroxylation is regulated by a family of
oxygen-dependent dioxygenases (PHD). Proper folding and
formation of the collagen triple helix requires 4hydroxylation of proline on the GPX repeat region, which is
catalyzed by Collagen P4H (cP4H).
CP4H is a α2β2 tetrameric α-KG-dependent dioxygenase, and succinate is a product of the hydroxylation reaction. Three α subunits (P4HA) of cP4H have been identified
in mammalian cells, and they are responsible for both peptide binding and for catalytic activity. P4HA1 is the major
isoform and contributes the majority of prolyl 4hydroxylase activity in most cell types and tissues. Recently,
studies showed that expression of P4HA1, 2 and 3 is induced during cancer development and progression, and
that increased P4HA expression correlates with poor prognosis in cancer patient. Importantly, P4HA1 expression in
cancer cells is required for breast cancer metastasis. However, we know little about how expression of P4HA1 in
cancer cells promotes tumor progression.
Using unbiased gene coexpression analysis, we have
identified the HIF-1 pathway as a potential downstream
target of P4HA1. CP4H has three-fold higher affinity to
α-KG and six-fold higher affinity to oxygen compared to
PHD, and about 38% of proline in collagen are hydroxylated. Therefore, increased expression of cP4H may compete
with PHD to consume a substantial amount of α-KG (Figure
1). Indeed, we found that cytoplasmic α-KG levels are reduced in P4HA1-expressing cells. Rescue experiments further confirm the hypothesis that P4HA1 regulates HIF-1α
stability by modulating α-KG and succinate levels. Regulation of HIF-1α stability with small metabolites has also
been demonstrated in glioma. Mutation of IDH-1 in glioma
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P4HA1 induces the HIf-1 pathway

FIGURE 1: A scheme showing the molecular mechanism by which cP4H1 enhances HIF-1stability and cancer cell stemness in TNBC.

induces the HIF-1 pathway by reducing α-KG production.
Our results suggest that metabolites such as α-KG and succinate are regulated by cP4H1 in TNBC, which in turn contributes to HIF-1 activation during breast cancer development and progression. It has been shown that lysyl oxidase
(LOX) expression also increases HIF-1α protein levels. Similar mechanisms may mediate the crosstalk between LOX
and HIF-1α. In addition, P4HA1 expression may modulate
activity of other α-KG-dependent enzymes, such as TET
enzymes and JMJD histone demethylases.
HIF-1 pathway is hyperactivated in TNBC and is associated with poor prognosis. We found that expression of the
HIF-1 gene signature correlates with P4AH1 levels in breast
cancer tissue samples. Tissue microarray data showed that
P4HA1 protein expression is significantly upregulated in
TNBC compared to ER positive breast cancer. These results
indicate that activation of the HIF-1 pathway in TNBC is at
least partially regulated by the P4HA1. However, other
mechanisms may also contribute to the HIF-1 activation in
TNBC. For instance, XBP1 interacts with HIF-1α and enhances its transcription factor activity and subsequently
drives TNBC tumorigenicity. In addition, SHARP1 suppresses breast cancer metastasis by promoting proteasomal
degradation of HIFs.
Activation of the HIF-1 pathway is crucial for the survival and self-renewal of stem cells. Cancer stem cells are
the driver of cancer progression and chemoresistance.
Interestingly, P4HA1 expression is upregulated in cancer
stem cell enriched cell population. We further demonstrated that P4HA1 regulates cancer cell stemness through the
HIF-1 pathway. Importantly, silence or inhibition of P4HA1
activity sensitizes TNBC to chemotherapeutic agents in
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vitro and in vivo. Moreover, high levels of P4HA1 are associated with chemoresistance in TNBC patients. These results indicate that targeting P4HA1 is a promising strategy
to inhibit cancer stem cells and overcome chemoresistance
in TNBC.
In summary, our findings fill a critical gap in our
knowledge about the regulation of the HIF-1 pathway and
tumor-initiating cells during breast cancer progression.
Given that activation of HIF-1 and expression of P4HA1 are
particularly robust in TNBC, inhibition of P4HA1 is a promising strategy for blocking TNBC progression. Therefore, it
is crucial to identify specific P4HA1 inhibitor in the future.
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